Extracorporeal photopheresis in solid organ transplantation

Cover Page


Cite item

Full Text

Abstract

Despite the use of up-to-date immunosuppressive agents, graft rejection episodes are quite common and pose a serious threat to thousands of solid organ recipients. Continuous use of various combinations of immunosuppressants cause serious complications, such as arterial hypertension, post-transplant diabetes mellitus, renal failure, increased risk of infections, malignant neoplasms, etc. The attempts to achieve the desired or forced minimization of the graft immunosuppression are associated with the threat of its rejection, which makes it necessary to search for less toxic, non-medical, immunological, including cellular, management methods. One of the promising methods based on cell technology is extracorporeal photopheresis (ECP). ECP is a well-established second line therapy recommended for the prevention and treatment of refractory rejection of a heart transplant. ECP improves the pulmonary allograft functioning in patients with treatment resistant obliterating bronchiolitis syndrome. However, its value as a preventive method has not yet been established. ECP effectiveness for induction, maintenance, or anti-crisis therapy in transplantation of kidney, liver or other solid organs has been rather convincing, but the lack of randomized multicenter studies limits its use. The optimal ECP strategy has not been yet established. Nevertheless, current understanding of the pathophysiological and immunological aspects of ECP is sufficient to develop a standard methodology and technology for the procedure, as well as for a quality control system for ECP in kidney and liver transplant recipients. The review discusses possible mechanisms of the immunomodulating effect of ECP. ECP is being increasingly studied in prospective randomized trials with larger samples. This allows for an extension of its clinical indications with clear criteria, as well as for studying its multifactorial underlying immunomodulating mechanism of action. Further research is needed to identify biomarkers that could predict ECP effectiveness in solid organ transplantation.

About the authors

A. V. Kildyushevsky

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: kildushev@yandex.ru
ORCID iD: 0000-0002-7079-8383

Alexander V. Kildyushevsky – MD, PhD, Professor, Leading Research Fellow, Department of Clinical Hematology and Immunotherapy

61/2 Shchepkina ul., Moscow, 129110

Tel.: +7 (903) 614 86 65

Russian Federation

Ya. G. Moysyuk

Moscow Regional Research and Clinical Institute (MONIKI)

Email: moysyuktrans@list.ru
ORCID iD: 0000-0002-0002-9183

Yan G. Moysyuk – MD, PhD, Professor, Head of Department of Transplantology

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

A. V. Molochkov

Moscow Regional Research and Clinical Institute (MONIKI)

Email: a.molochkov@monikiweb.ru
ORCID iD: 0000-0002-6456-998X

Anton V. Molochkov – MD, PhD, Professor, Deputy Director

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

T. A. Mitina

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fmi_69@inbox.ru
ORCID iD: 0000-0001-7493-0030

Tatiana A. Mitina – MD, PhD, Head of the Department of Clinical Hematology and Immunotherapy

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

A. P. Faenko

Moscow Regional Research and Clinical Institute (MONIKI)

Email: alexfaenko@mail.ru
ORCID iD: 0000-0001-6158-233X

Alexandr P. Faenko – MD, PhD, Associate Professor, Course of Clinical Transfusiology, Chair of Anesthesiology and Intensive Care, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

References

  1. Mueller NJ. New immunosuppressive strategies and the risk of infection. Transpl Infect Dis. 2008;10(6): 379–84. doi: 10.1111/j.1399-3062.2008.00346.x.
  2. Zafar SY, Howell DN, Gockerman JP. Malignancy after solid organ transplantation: an overview. Oncologist. 2008;13(7): 769–78. doi: 10.1634/theoncologist.2007-0251.
  3. Golshayan D, Pascual M. Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview. Drugs. 2008;68(15): 2113–30. doi: 10.2165/00003495-200868150-00004.
  4. Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood. 2002;100(3): 941–7. doi: 10.1182/blood-2002-01-0068.
  5. Heshmati F. Mechanisms of action of extracorporeal photochemotherapy. Transfus Apher Sci. 2003;29(1): 61–70. doi: 10.1016/S1473-0502(03)00103-4.
  6. Marshall SR. Technology insight: ECP for the treatment of GvHD – can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol. 2006;3(6): 302–14. doi: 10.1038/ncponc0511.
  7. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med. 1987;316(6): 297–303. doi: 10.1056/NEJM198702053160603.
  8. Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, Juvonen E, Marshall S; Photopheresis Expert Group. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol. 2008;158(4): 659–78. doi: 10.1111/j.1365-2133.2007.08415.x.
  9. Salvaneschi L, Perotti C, Zecca M, Bernuzzi S, Viarengo G, Giorgiani G, Del Fante C, Bergamaschi P, Maccario R, Pession A, Locatelli F. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion. 2001;41(10): 1299–305. doi: 10.1046/j.1537-2995.2001.41101299.x.
  10. Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant. 2002;29(9): 719–25. doi: 10.1038/sj.bmt.1703529.
  11. Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher. 2002;6(4): 296–304. doi: 10.1046/j.1526-0968.2002.00448.x.
  12. Jagasia M, Greinix H, Robin M, Das-Gupta E, Jacobs R, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Socie G. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. Biol Blood Marrow Transplant. 2013;19(7): 1129–33. doi: 10.1016/j.bbmt.2013.04.018.
  13. Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol. 2013;4(5): 320–34. doi: 10.1177/2040620713490316.
  14. Pierelli L, Perseghin P, Marchetti M, Messina C, Perotti C, Mazzoni A, Bacigalupo A, Locatelli F, Carlier P, Bosi A; Società Italiana di Emaferesi and Manipolazione Cellulare (SIdEM); Gruppo Italiano Trapianto Midollo Osseo (GITMO). Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion. 2013;53(10): 2340–52. doi: 10.1111/trf.12059.
  15. Yoo EK, Rook AH, Elenitsas R, Gasparro FP, Vowels BR. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol. 1996;107(2): 235–42. doi: 10.1111/1523-1747.ep12329711.
  16. Whittle RM, Denney H, Chantry AD, Alfred A, Taylor PC. Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease. J Clin Apher. 2017;32(6): 462–73. doi: 10.1002/jca.21541.
  17. Perseghin P. Extracorporeal Photochemotherapy as a Challenging Treatment for Cutaneous T-Cell Lymphoma, Acute and Chronic Graftversus-Host Disease, Organ Rejection and T-Lymphocyte-Mediated Autoimmune Diseases. Transfus Med Hemother. 2008;35(1): 8–17. doi: 10.1159/000111755.
  18. Hillen U, Meyer S, Schadendorf D, Kremens B. Photopheresis in pediatric patients with low-body weight using the UVAR XTS system. J Dtsch Dermatol Ges. 2010;8(1): 32–7. English, German. doi: 10.1111/j.1610-0387.2009.07212.x.
  19. Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34(3): 171–354. doi: 10.1002/jca.21705.
  20. Andreu G, Leon A, Heshmati F, Tod M, Menkes CJ, Baudelot J, Laroche L. Extracorporeal photochemotherapy: evaluation of two techniques and use in connective tissue disorders. Transfus Sci. 1994;15(4): 443–54. doi: 10.1016/0955-3886(94)90178-3.
  21. Andreola G, Babic A, Perseghin P, Crovetti G. Extracorporeal photochemotherapy: an Italian panel perspective on indications, methodologies and clinical results. Drugs Cell Ther Hematol. 2013;2(2): 122–32. doi: 10.4081/dcth.2013.122.
  22. Brosig A, Hähnel V, Orsó E, Wolff D, Holler E, Ahrens N. Technical comparison of four different extracorporeal photopheresis systems. Transfusion. 2016;56(10): 2510–9. doi: 10.1111/trf.13728.
  23. Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L, Ludvigsson J, Quaglino P, Reinisch W, Scarisbrick J, Schwarz T, Wolf P, Arenberger P, Assaf C, Bagot M, Barr M, Bohbot A, Bruckner-Tuderman L, Dreno B, Enk A, French L, Gniadecki R, Gollnick H, Hertl M, Jantschitsch C, Jung A, Just U, Klemke CD, Lippert U, Luger T, Papadavid E, Pehamberger H, Ranki A, Stadler R, Sterry W, Wolf IH, Worm M, Zic J, Zouboulis CC, Hillen U. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28 Suppl 1(Suppl 1): 1–37. doi: 10.1111/jdv.12311.
  24. Società Italiana di Emaferesi e Manipolazione Cellulare. International Standards for Therapeutic Apheresis Units [Internet]. 1st ed. Version 1.7. Nov 2014.
  25. Howell C, Douglas K, Cho G, El-Ghariani K, Taylor P, Potok D, Rintala T, Watkins S. Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for Standards in Haematology. Transfus Med. 2015;25(2): 57–78. doi: 10.1111/tme.12205.
  26. Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, Bonney D, Das-Gupta E, Lawson S, Malladi RK, Douglas KW, Maher T, Guest J, Hartlett L, Fisher AJ, Child F, Scarisbrick JJ. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol. 2017;177(2): 287–310. doi: 10.1111/bjh.14537.
  27. Christie JD, Edwards LB, Aurora P, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Taylor DO, Kucheryavaya AY, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant. 2009;28(10): 1031–49. doi: 10.1016/j.healun.2009.08.004.
  28. Khan UA, Williams SG, Fildes JE, Shaw SM. The pathophysiology of chronic graft failure in the cardiac transplant patient. Am J Transplant. 2009;9(10): 2211–6. doi: 10.1111/j.1600-6143.2009.02807.x.
  29. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, Johnson MR, Mullen GM, Heroux AL, Kao WG, McManus BM, Pifarre R, Robinson JA. Photopheresis versus corticosteroids in the therapy of heart transplant rejection. Preliminary clinical report. Circulation. 1992;86(5 Suppl): II242–50.
  30. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, Johnson MR, Mullen GM, Heroux AL, Kao WG, McManus BM, Pifarre R, Robinson JA. Successful treatment of heart transplant rejection with photopheresis. Transplantation. 1992;53(4): 808–15. doi: 10.1097/00007890-199204000-00021.
  31. Costanzo-Nordin MR, McManus BM, Wilson JE, O'Sullivan EJ, Hubbell EA, Robinson JA. Efficacy of photopheresis in the rescue therapy of acute cellular rejection in human heart allografts: a preliminary clinical and immunopathologic report. Transplant Proc. 1993;25(1 Pt 2): 881–3.
  32. Rose EA, Barr ML, Xu H, Pepino P, Murphy MP, McGovern MA, Ratner AJ, Watkins JF, Marboe CC, Berger CL. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant. 1992;11(4 Pt 1): 746–50.
  33. Dall'Amico R, Livi U, Milano A, Montini G, Andreetta B, Murer L, Zacchello G, Thiene G, Casarotto D, Zacchello F. Extracorporeal photochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation. 1995;60(1): 45–9. doi: 10.1097/00007890-199507150-00009.
  34. Dall'Amico R, Montini G, Murer L, Andreetta B, Tursi V, Feltrin G, Guzzi G, Angelini A, Zacchello G, Livi U. Benefits of photopheresis in the treatment of heart transplant patients with multiple/refractory rejection. Transplant Proc. 1997;29(1–2): 609–11. doi: 10.1016/s0041-1345(96)00323-5.
  35. Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dall'Amico R, Dorent R, Rogers JG, Radovancević B, Taylor DO, Jeevanandam V, Marboe CC. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med. 1998;339(24): 1744–51. doi: 10.1056/NEJM199812103392404.
  36. Barr ML, Baker CJ, Schenkel FA, McLaughlin SN, Stouch BC, Starnes VA, Rose EA. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant. 2000;14(2): 162–6. doi: 10.1034/j.1399-0012.2000.140211.x.
  37. Dall'Amico R, Montini G, Murer L, Andreetta B, Zacchello G, Gambino A, Feltrin G, Caforio A, Tursi V, Livi U. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. Int J Artif Organs. 2000;23(1): 49–54.
  38. Kirklin JK, Brown RN, Huang ST, Naftel DC, Hubbard SM, Rayburn BK, McGiffin DC, Bourge RB, Benza RL, Tallaj JA, Pinderski LJ, Pamboukian SV, George JF, Marques M. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant. 2006;25(3): 283–8. doi: 10.1016/j.healun.2005.10.004.
  39. Barten MJ, Dieterlen MT. Extracorporeal photopheresis after heart transplantation. Immunotherapy. 2014;6(8): 927–44. doi: 10.2217/imt.14.69.
  40. Savignano C, Rinaldi C, Tursi V, Dolfini C, Isola M, Livi U, De Angelis V. Extracorporeal photochemotherapy in heart transplant rejection: A single-center experience. Transfus Apher Sci. 2017;56(4): 520–4. doi: 10.1016/j.transci.2017.07.009.
  41. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3): 83–177. doi: 10.1002/jca.20240.
  42. Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31(3): 149–62. doi: 10.1002/jca.21470.
  43. Patel J, Klapper E, Shafi H, Kobashigawa JA. Extracorporeal photopheresis in heart transplant rejection. Transfus Apher Sci. 2015;52(2): 167–70. doi: 10.1016/j.transci.2015.02.004.
  44. Colvin MM, Cook JL, Chang P, Francis G, Hsu DT, Kiernan MS, Kobashigawa JA, Lindenfeld J, Masri SC, Miller D, O'Connell J, Rodriguez ER, Rosengard B, Self S, White-Williams C, Zeevi A; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Radiology and Intervention; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Surgery and Anesthesia. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015;131(18): 1608–39. doi: 10.1161/CIR.0000000000000093.
  45. Bemiss BC, Witt CA. Chronic lung allograft dysfunction following lung transplantation: challenges and solutions. Transplant Res Risk Manage. 2014;6:87–97. doi: 10.2147/TRRM.S50896.
  46. Yusen RD, Edwards LB, Dipchand AI, Goldfarb SB, Kucheryavaya AY, Levvey BJ, Lund LH, Meiser B, Rossano JW, Stehlik J; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant. 2016;35(10): 1170–84. doi: 10.1016/j.healun.2016.09.001.
  47. Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs. 2007;67(11): 1531–9. doi: 10.2165/00003495-200767110-00002.
  48. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014;33(2): 127–33. doi: 10.1016/j.healun.2013.10.022.
  49. Verleden SE, Vandermeulen E, Ruttens D, Vos R, Vaneylen A, Dupont LJ, Van Raemdonck DE, Vanaudenaerde BM, Verleden GM. Neutrophilic reversible allograft dysfunction (NRAD) and restrictive allograft syndrome (RAS). Semin Respir Crit Care Med. 2013;34(3): 352–60. doi: 10.1055/s-0033-1348463.
  50. Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2005;5(3): 537–43. doi: 10.1111/j.1600-6143.2004.00709.x.
  51. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85(1): 36–41. doi: 10.1097/01.tp.0000295981.84633.bc.
  52. Groves S, Galazka M, Johnson B, Corcoran T, Verceles A, Britt E, Todd N, Griffith B, Smaldone GC, Iacono A. Inhaled cyclosporine and pulmonary function in lung transplant recipients. J Aerosol Med Pulm Drug Deliv. 2010;23(1): 31–9. doi: 10.1089/jamp.2009.0748.
  53. Iacono AT, Johnson BA, Grgurich WF, Youssef JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, Griffith BP. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354(2): 141–50. doi: 10.1056/NEJMoa043204.
  54. Snell GI, Valentine VG, Vitulo P, Glanville AR, McGiffin DC, Loyd JE, Roman A, Aris R, Sole A, Hmissi A, Pirron U; RAD B159 Study Group. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant. 2006;6(1): 169–77. doi: 10.1111/j.1600-6143.2005.01134.x.
  55. Benden C, Haughton M, Leonard S, Huber LC. Therapy options for chronic lung allograftdysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review. J Heart Lung Transplant. 2017;36(9): 921–33. doi: 10.1016/j.healun.2017.05.030.
  56. Andreu G, Achkar A, Couetil JP, Guillemain R, Heshmati F, Amrein C, Chevalier P, Guinvarch A, Dore MF, Capron F, et al. Extracorporeal photochemotherapy treatment for acute lung rejection episode. J Heart Lung Transplant. 1995;14(4): 793–6.
  57. Slovis BS, Loyd JE, King LE Jr. Photopheresis for chronic rejection of lung allografts. N Engl J Med. 1995;332(14): 962. doi: 10.1056/NEJM199504063321417.
  58. O'Hagan AR, Stillwell PC, Arroliga A, Koo A. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest. 1999;115(5): 1459–62. doi: 10.1378/chest.115.5.1459.
  59. Villanueva J, Bhorade SM, Robinson JA, Husain AN, Garrity ER Jr. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant. 2000;5(3): 44–7.
  60. Salerno CT, Park SJ, Kreykes NS, Kulick DM, Savik K, Hertz MI, Bolman RM 3rd. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. J Thorac Cardiovasc Surg. 1999;117(6): 1063–9. doi: 10.1016/s0022-5223(99)70241-2.
  61. Benden C, Speich R, Hofbauer GF, Irani S, Eich-Wanger C, Russi EW, Weder W, Boehler A. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation. 2008;86(11): 1625–7. doi: 10.1097/TP.0b013e31818bc024.
  62. Astor TL, Weill D. Extracorporeal photopheresis in lung transplantation. J Cutan Med Surg. 2003;7(4 Suppl):20–4. doi: 10.1007/s10227-003-5005-x.
  63. Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010;29(4): 424–31. doi: 10.1016/j.healun.2009.08.029.
  64. Jaksch P, Scheed A, Keplinger M, Ernst MB, Dani T, Just U, Nahavandi H, Klepetko W, Knobler R. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2012;31(9): 950–7. doi: 10.1016/j.healun.2012.05.002.
  65. Barr ML. Call it BOS, call it CLAD – the need for prospective clinical trials and elucidating the mechanism of extracorporeal photopheresis. Am J Transplant. 2013;13(4): 833–4. doi: 10.1111/ajt.12158.
  66. Greer M, Dierich M, De Wall C, Suhling H, Rademacher J, Welte T, Haverich A, Warnecke G, Ivanyi P, Buchholz S, Gottlieb J, Fuehner T. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. Am J Transplant. 2013;13(4): 911–8. doi: 10.1111/ajt.12155.
  67. ClinicalTrials.gov. Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts (ECP) [Internet]. 2014 Jul 3. Updated 2020 Aug 26. Available from: https://clinicaltrials.gov/ct2/show/NCT02181257.
  68. Gaston RS, Fieberg A, Hunsicker L, Kasiske BL, Leduc R, Cosio FG, Gourishankar S, Grande J, Mannon RB, Rush D, Cecka JM, Connett J, Matas AJ. Late graft failure after kidney transplantation as the consequence of late versus early events. Am J Transplant. 2018;18(5): 1158–67. doi: 10.1111/ajt.14590.
  69. Lamb KE, Lodhi S, Meier-Kriesche HU. Longterm renal allograft survival in the United States: a critical reappraisal. Am J Transplant. 2011;11(3): 450–62. doi: 10.1111/j.1600-6143.2010.03283.x.
  70. Keith DS, Vranic G, Nishio-Lucar A. Graft Function and Intermediate-Term Outcomes of Kidney Transplants Improved in the Last Decade: Analysis of the United States Kidney Transplant Database. Transplant Direct. 2017;3(6):e166. doi: 10.1097/TXD.0000000000000654.
  71. Koo EH, Jang HR, Lee JE, Park JB, Kim SJ, Kim DJ, Kim YG, Oh HY, Huh W. The impact of early and late acute rejection on graft survival in renal transplantation. Kidney Res Clin Pract. 2015;34(3): 160–4. doi: 10.1016/j.krcp.2015.06.003.
  72. Jalalzadeh M, Mousavinasab N, Peyrovi S, Ghadiani MH. The impact of acute rejection in kidney transplantation on long-term allograft and patient outcome. Nephrourol Mon. 2015;7(1):e24439. doi: 10.5812/numonthly.24439.
  73. Pesce F, Martino M, Fiorentino M, Rollo T, Simone S, Gallo P, Stallone G, Grandaliano G, Schena A, Margiotta M, Mininni D, Palieri R, Lucarelli G, Battaglia M, Gesualdo L, Castellano G. Recurrent urinary tract infections in kidney transplant recipients during the first-year influence longterm graft function: a single-center retrospective cohort study. J Nephrol. 2019;32(4): 661–8. doi: 10.1007/s40620-019-00591-5.
  74. Столяревич ЕС, Жилинская ТР, Артюхина ЛЮ, Ким ИГ, Зайденов ВА, Томилина НА. Морфологическая структура патологии почечного аллотрансплантата и ее влияние на отдаленный прогноз. Вестник трансплантологии и искусственных органов. 2018;20(1): 45–54. doi: 10.15825/1995-1191-2018-1-45-54.
  75. Horina JH, Müllegger RR, Horn S, Holzer H, Halwachs G, Kerl H, Wolf P. Photopheresis for renal allograft rejection. Lancet. 1995;346(8966): 61. doi: 10.1016/s0140-6736(95)92696-8.
  76. Sunder-Plassman G, Druml W, Steininger R, Hönigsmann H, Knobler R. Renal allograft rejection controlled by photopheresis. Lancet. 1995;346(8973): 506. doi: 10.1016/s0140-6736(95)91355-6.
  77. Genberg H, Kumlien G, Shanwell A, Tydén G. Refractory acute renal allograft rejection successfully treated with photopheresis. Transplant Proc. 2005;37(8): 3288–9. doi: 10.1016/j.transproceed.2005.09.003.
  78. Fernández EJ, López C, Ramírez A, Guerra R, López L, Fernández F, Tapia M, García-Cantón C. Role of photopheresis in the treatment of refractory cellular rejection in kidney transplantation. Nefrologia. 2016;36(3): 327–8. English, Spanish. doi: 10.1016/j.nefro.2015.06.023.
  79. Kumlien G, Genberg H, Shanwell A, Tydén G. Photopheresis for the treatment of refractory renal graft rejection. Transplantation. 2005;79(1): 123–5. doi: 10.1097/01.tp.0000147197.24050.61.
  80. Lai Q, Pretagostini R, Gozzer M, Cinti P, Meo D, Vita F, Shafii Bafti M, Poli L, Novelli G, Rossi M, Girelli G, Berloco PB. Multimodal therapy with combined plasmapheresis, photoapheresis, and intravenous immunoglobulin for acute antibody-mediated renal transplant rejection: a 2-year follow-up. Transplant Proc. 2011;43(4): 1039–41. doi: 10.1016/j.transproceed.2011.03.023.
  81. Lamioni A, Carsetti R, Legato A, Landolfo A, Isacchi G, Emma F, Bottazzo GF, Dello Strologo L. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation. 2007;83(10): 1393–6. doi: 10.1097/01.tp.0000261635.30578.d8.
  82. Kusztal M, Kościelska-Kasprzak K, Gdowska W, Zabińska M, Myszka M, Kłak R, Krajewska M, Boratyńska M, Szyber P, Chudoba P, Patrzałek D, Klinger M. Extracorporeal photopheresis as an antirejection prophylaxis in kidney transplant recipients: preliminary results. Transplant Proc. 2011;43(8): 2938–40. doi: 10.1016/j.transproceed.2011.08.061.
  83. Федулкина ВА, Ватазин АВ, Кильдюшевский АВ, Столяревич ЕС, Кантария РО, Зулькарнаев АБ. Трансляционная клеточная иммунотерапия при аллотрансплантации трупной почки у урологических больных. Альманах клинической медицины. 2013;28:25–31. doi: 10.18786/2072-0505-2013-28-25-31.
  84. Фаенко АП, Зулькарнаев АБ, Федулкина ВА, Кантария РО, Кильдюшевский АВ, Ватазин АВ. Отдаленные клинические результаты применения фотофереза в качестве профилактики отторжения почечного аллотрансплантата. Клиническая нефрология. 2018;(2): 37–42. doi: 10.18565/nephroiogy.2018.2.37-42.
  85. Фаенко АП, Зулькарнаев АБ, Чуксина ЮЮ, Федулкина ВА, Кантария РО, Кильдюшевский АВ, Ватазин АВ. Отдаленные результаты профилактического применения фотофереза при трансплантации почки. Вестник трансплантологии и искусственных органов. 2018;20(1): 55–65. doi: 10.15825/1995-1191-2018-1-55-65.
  86. Шифф ЮР, Соррел МФ, Мэддрей УС. Болезни печени по Шиффу. Цирроз печени и его осложнения. Трансплантация печени. Пер. с англ. М.: ГЭОТАР-Медиа; 2012. 592 с.
  87. Шумаков ВИ, ред. Трансплантология: руководство для врачей. М.: Медицинское информационное агентство; 2006. 544 с.
  88. Busuttil R, Klintmalm G. Transplantation of the liver. 3rd edition. Philadelphia: Elsevier Saunders; 2015. 1568 p.
  89. Abbasoglu O, Levy MF, Brkic BB, Testa G, Jeyarajah DR, Goldstein RM, Husberg BS, Gonwa TA, Klintmalm GB. Ten years of liver transplantation: an evolving understanding of late graft loss. Transplantation. 1997;64(12): 1801–7. doi: 10.1097/00007890-199712270-00030.
  90. Neuberger J. Liver transplantation. J Hepatol. 2000;32(1 Suppl):198–207. doi: 10.1016/s0168-8278(00)80426-2.
  91. Sudan DL, Venkataramani A, Lynch J, Lynch JC, Fox IJ, Jr Shaw BW, Langnas AN. Causes of late mortality in survivors of liver transplantation. Transplantation. 1999;67:S564.
  92. Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg. 2001;181(5): 475–9. doi: 10.1016/s0002-9610(01)00595-5.
  93. Gelson W, Hoare M, Dawwas MF, Vowler S, Gibbs P, Alexander G. The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation. 2011;91(11): 1240–4. doi: 10.1097/TP.0b013e31821841ba.
  94. Asfar S, Metrakos P, Fryer J, Verran D, Ghent C, Grant D, Bloch M, Burns P, Wall W. An analysis of late deaths after liver transplantation. Transplantation. 1996;61(9): 1377–81. doi: 10.1097/00007890-199605150-00016.
  95. Wallia A, Parikh ND, Molitch ME, Mahler E, Tian L, Huang JJ, Levitsky J. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. Transplantation. 2010;89(2): 222–6. doi: 10.1097/TP.0b013e3181c3c2ff.
  96. Gómez-Manero N, Herrero JI, Quiroga J, Sangro B, Pardo F, Cienfuegos JA, Prieto J. Prognostic model for early acute rejection after liver transplantation. Liver Transpl. 2001;7(3): 246–54. doi: 10.1053/jlts.2001.22460. Erratum in: Liver Transpl. 2002;8(6): 573.
  97. Ziolkowski J, Paczek L, Niewczas M, Senatorski G, Oldakowska-Jedynak U, Wyzgal J, Foroncewicz B, Mucha K, Zegarska J, Nyckowski P, Zieniewicz K, Patkowski W, Krawczyk M, Ziarkiewicz-Wroblewska B, Gornicka B. Acute liver transplant rejection: incidence and the role of high-doses steroids. Transplant Proc. 2003;35(6): 2289–91. doi: 10.1016/s0041-1345(03)00797-8.
  98. Devlin J, Doherty D, Thomson L, Wong T, Donaldson P, Portmann B, Williams R. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology. 1998;27(4): 926–33. doi: 10.1002/hep.510270406.
  99. Mazariegos GV, Ramos H, Shapiro R, Zeevi A, Fung JJ, Starzl TE. Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transplant Proc. 1995;27(1): 207–9.
  100. Pons JA, Yélamos J, Ramírez P, Oliver-Bonet M, Sánchez A, Rodríguez-Gago M, Navarro J, Bermejo J, Robles R, Parrilla P. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation. 2003;75(7): 1045–7. doi: 10.1097/01.TP.0000058472.71775.7D.
  101. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Fujita S, Hayashi M, Kanematsu T, Tanaka K. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation. 2001;72(3): 449–54. doi: 10.1097/00007890-200108150-00016.
  102. Calne RY. Prope tolerance: the future of organ transplantation – from the laboratory to the clinic. Transplantation. 2004;77(6): 930–2. doi: 10.1097/01.tp.0000117776.14277.03.
  103. Wieërs G, Gras J, Bourdeaux C, Truong DQ, Latinne D, Reding R. Monitoring tolerance after human liver transplantation. Transpl Immunol. 2007;17(2): 83–93. doi: 10.1016/j.trim.2006.09.020.
  104. Sánchez-Fueyo A, Strom TB. Immunological tolerance and liver transplantation. J Hepatol. 2004;41(5): 698–705. doi: 10.1016/j.jhep.2004.09.013.
  105. Pons JA, Revilla-Nuin B, Baroja-Mazo A, Ramírez P, Martínez-Alarcón L, Sánchez-Bueno F, Robles R, Rios A, Aparicio P, Parrilla P. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation. 2008;86(10): 1370–8. doi: 10.1097/TP.0b013e318188d3e6.
  106. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4): 330–6. doi: 10.1038/ni904.
  107. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3(3): 199–210. doi: 10.1038/nri1027.
  108. Li Y, Koshiba T, Yoshizawa A, Yonekawa Y, Masuda K, Ito A, Ueda M, Mori T, Kawamoto H, Tanaka Y, Sakaguchi S, Minato N, Wood KJ, Tanaka K. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant. 2004;4(12): 2118–25. doi: 10.1111/j.1600-6143.2004.00611.x.
  109. Martínez-Llordella M, Puig-Pey I, Orlando G, Ramoni M, Tisone G, Rimola A, Lerut J, Latinne D, Margarit C, Bilbao I, Brouard S, Hernández-Fuentes M, Soulillou JP, Sánchez-Fueyo A. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant. 2007;7(2): 309–19. doi: 10.1111/j.1600-6143.2006.01621.x.
  110. Louis S, Braudeau C, Giral M, Dupont A, Moizant F, Robillard N, Moreau A, Soulillou JP, Brouard S. Contrasting CD25hiCD4+ T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation. 2006;81(3): 398–407. doi: 10.1097/01.tp.0000203166.44968.86.
  111. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609): 1057–61. doi: 10.1126/science.1079490.
  112. Lehrer MS, Ruchelli E, Olthoff KM, French LE, Rook AH. Successful reversal of recalcitrant hepatic allograft rejection by photopheresis. Liver Transpl. 2000;6(5): 644–7. doi: 10.1053/jlts.2000.9745.
  113. Starzl TE, Murase N, Thomson A, Demetris AJ. Liver transplants contribute to their own success. Nat Med. 1996;2(2): 163–5. doi: 10.1038/nm0296-163.
  114. Starzl TE, Murase N, Demetris A, Trucco M, Fung J. The mystique of hepatic tolerogenicity. Semin Liver Dis. 2000;20(4): 497–510. doi: 10.1055/s-2000-13158.
  115. Starzl TE. The "privileged" liver and hepatic tolerogenicity. Liver Transpl. 2001;7(10): 918–20. doi: 10.1053/jlts.2001.0070918.
  116. Urbani L, Mazzoni A, De Simone P, Catalano G, Coletti L, Petruccelli S, Biancofiore G, Bindi L, Scatena F, Filipponi F. Avoiding calcineurin inhibitors in the early post-operative course in high-risk liver transplant recipients: The role of extracorporeal photopheresis. J Clin Apher. 2007;22(4): 187–94. doi: 10.1002/jca.20111.
  117. Urbani L, Mazzoni A, Bianco I, Grazzini T, De Simone P, Catalano G, Montin U, Petruccelli S, Morelli L, Campani D, Pollina L, Biancofiore G, Bindi L, Tascini C, Menichetti F, Scatena F, Filipponi F. The role of immunomodulation in ABO-incompatible adult liver transplant recipients. J Clin Apher. 2008;23(2): 55–62. doi: 10.1002/jca.20156.
  118. Mazzoni A, Giampietro C, Bianco I, Grazzini T, Nencini C, Pileggi C, Scatena F, Filipponi F, Ghinolfi D, Catalano G, Biancofiore G, Bindi ML, Urbani L. Extracorporeal photopheresis and liver transplantation: Our experience and preliminary data. Transfus Apher Sci. 2017;56(4): 515–9. doi: 10.1016/j.transci.2017.07.008.
  119. Urbani L, Mazzoni A, Catalano G, De Simone P, Vanacore R, Pardi C, Bortoli M, Biancofiore G, Campani D, Perrone V, Mosca F, Scatena F, Filipponi F. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. Transplant Proc. 2004;36(10): 3068–70. doi: 10.1016/j.transproceed. 2004.10.071.
  120. Urbani L, Mazzoni A, Colombatto P, Biancofiore G, Bindi L, Tascini C, Menichetti F, Brunetto M, Scatena F, Filipponi F. Potential applications of extracorporeal photopheresis in liver transplantation. Transplant Proc. 2008;40(4): 1175–8. doi: 10.1016/j.transproceed.2008.03.071.
  121. Perotti C, Torretta L, Viarengo G, Roveda L, Bernuzzi S, Carbone S, Del Fante C, La Torre R, Locatelli F, Bonetti F, Gabba P, Bellosta M, Salvaneschi L. Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica. 1999;84(3): 237–41.
  122. Jaksch P, Knobler R. ECP and solid organ transplantation. Transfus Apher Sci. 2014;50(3): 358–62. doi: 10.1016/j.transci.2014.04.006.
  123. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8): 1150–63. doi: 10.1016/j.bbmt.2012.04.005.
  124. Dall'Amico R, Murer L, Montini G, Andreetta B, Zanon GF, Zacchello G, Zacchello F. Successful treatment of recurrent rejection in renal transplant patients with photopheresis. J Am Soc Nephrol. 1998;9(1): 121–7.
  125. Bambauer R, Schneidewind-Müller JM, Schiel R, Latza R. Side-effects and complications in large-bore catheters for apheresis. Ther Apher Dial. 2003;7(2): 221–4. doi: 10.1046/j.1526-0968.2003.00033.x.
  126. Edelson BT, Donnelly JK, Cox-Potter TS, Shah KS, Dynis MS, Lublin DM. Heparin low . . . photo no! Transfusion. 2006;46(5): 683–4. doi: 10.1111/j.1537-2995.2006.00784.x.
  127. Bladon J, Taylor PC. Extracorporeal photopheresis in cutaneous T-cell lymphoma and graftversus-host disease induces both immediate and progressive apoptotic processes. Br J Dermatol. 2002;146(1): 59–68. doi: 10.1046/j.1365-2133.2002.04560.x.
  128. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher. 2006;21(1): 72–7. doi: 10.1002/jca.20089.
  129. Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, Renoldi G, Parma M, Balduzzi A, Perseghin P, Biondi A. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+ CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007;84(1): 31–9. doi: 10.1097/01.tp.0000267785.52567.9c.
  130. Lamioni A, Parisi F, Isacchi G, Giorda E, Di Cesare S, Landolfo A, Cenci F, Bottazzo GF, Carsetti R. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation. 2005;79(7): 846–50. doi: 10.1097/01.tp.0000157278.02848.c7.
  131. Lamioni A, Carsetti R, Legato A, Landolfo A, Isacchi G, Emma F, Bottazzo GF, Dello Strologo L. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation. 2007;83(10): 1393–6. doi: 10.1097/01.tp.0000261635.30578.d8.
  132. Meloni F, Cascina A, Miserere S, Perotti C, Vitulo P, Fietta AM. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc. 2007;39(1): 213–7. doi: 10.1016/j.transproceed.2006.10.227.
  133. Dieterlen MT, Bittner HB, Pierzchalski A, Dhein S, Mohr FW, Barten MJ. Immunological monitoring of extracorporeal photopheresis after heart transplantation. Clin Exp Immunol. 2014;176(1): 120–8. doi: 10.1111/cei.12254.
  134. Lorenz K, Rommel K, Mani J, Jin N, Hilgendorf I, Ho AD, Freund M, Schmitt M, Schmitt A. Modulation of lymphocyte subpopulations by extracorporeal photopheresis in patients with acute graft-versus-host disease or graft rejection. Leuk Lymphoma. 2015;56(3): 671–5. doi: 10.3109/10428194.2014.931956.
  135. Baskaran G, Tiriveedhi V, Ramachandran S, Aloush A, Grossman B, Hachem R, Mohanakumar T. Efficacy of extracorporeal photopheresis in clearance of antibodies to donor-specific and lung-specific antigens in lung transplant recipients. J Heart Lung Transplant. 2014;33(9): 950–6. doi: 10.1016/j.healun.2014.04.020.
  136. Hachem R, Corris P. Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation. Transplantation. 2018;102(7): 1059–65. doi: 10.1097/TP.0000000000002168.
  137. Berger CL, Hanlon D, Kanada D, Girardi M, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. Transfus Apher Sci. 2002;26(3): 205–16. doi: 10.1016/s1473-0502(02)00014-9.
  138. Spisek R, Gasova Z, Bartunkova J. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion. 2006;46(1): 55–65. doi: 10.1111/j.1537-2995.2005.00670.x.
  139. Gasparro FP, Felli A, Schmitt IM. Psoralen photobiology: the relationship between DNA damage, chromatin structure, transcription, and immunogenic effects. Recent Results Cancer Res. 1997;143:101–27. doi: 10.1007/978-3-642-60393-8_8.
  140. Marks DI, Fox RM. Mechanisms of photochemotherapy-induced apoptotic cell death in lymphoid cells. Biochem Cell Biol. 1991;69(10–11): 754–60. doi: 10.1139/o91-115.
  141. Gatza E, Rogers CE, Clouthier SG, Lowler KP, Tawara I, Liu C, Reddy P, Ferrara JL. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112(4): 1515–21. doi: 10.1182/blood-2007-11-125542.
  142. Berger CL, Xu AL, Hanlon D, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, Edelson RL. Induction of human tumor-loaded dendritic cells. Int J Cancer. 2001;91(4): 438–47. doi: 10.1002/1097-0215(200002)9999:9999<::aidijc1073> 3.0.co;2-r.
  143. Becherucci V, Allegro E, Brugnolo F, Piccini L, Gori V, Bisin S, Bindi B, Ceccantini R, Pavan P, Cunial V, Gentile F, Ermini S, Bambi F. Extracorporeal photopheresis as an immunomodulatory agent: Haematocrit-dependent effects on natural killer cells. J Clin Apher. 2017;32(4): 257–65. doi: 10.1002/jca.21490.
  144. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193(11): 1285–94. doi: 10.1084/jem.193.11.1285.
  145. Casey MJ, Meier-Kriesche HU. Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens. 2011;20(6): 610–5. doi: 10.1097/MNH.0b013e32834b4343.
  146. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant. 2011;11(6): 1226–35. doi: 10.1111/j.1600-6143.2011.03539.x.
  147. Newell KA, Phippard D, Turka LA. Regulatory cells and cell signatures in clinical transplantation tolerance. Curr Opin Immunol. 2011;23(5): 655–9. doi: 10.1016/j.coi.2011.07.008.
  148. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature. 1953;172(4379): 603–6. doi: 10.1038/172603a0.
  149. Xu H, Ildstad ST. Transplantation: is donor T-cell engraftment a biomarker for tolerance? Nat Rev Nephrol. 2012;8(10): 560–1. doi: 10.1038/nrneph.2012.187.
  150. Хаитов РМ, Игнатьева ГА, Сидорович ИГ. Иммунология. М.: Медицина; 2000. 432 с.
  151. Levitsky J. Next level of immunosuppression: drug/immune monitoring. Liver Transpl. 2011;17 Suppl 3:S60–5. doi: 10.1002/lt.22385.
  152. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2): 481–508. doi: 10.2215/CJN.04800908.
  153. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, Scheller D, Ersfeld D, Frick M, Fitzsimmons WE, Virji M, Jain A, Brayman KL, Shaked A. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41(5): 542–51. doi: 10.1177/00912700122010429.
  154. Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25): 2562–75. doi: 10.1056/NEJMoa067411.
  155. Rovira P, Mascarell L, Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem. 2000;7(7): 673–92. doi: 10.2174/0929867003374778.
  156. Wieland E, Olbricht CJ, Süsal C, Gurragchaa P, Böhler T, Israeli M, Sommerer C, Budde K, Hartmann B, Shipkova M, Oellerich M. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit. 2010;32(5): 560–72. doi: 10.1097/FTD.0b013e3181efb3d2.
  157. U.S. Food & Drug Administration. Cyclosporine and Tacrolimus Assays – Class II Special Controls Guidance Document for Industry and FDA [Internet]. 2002 Sep 16. Available from: https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/cyclosporine-and-tacrolimus-assays-class-ii-special-controls-guidance-document-industry-and-fda.
  158. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing KF. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos. 1995;23(12): 1315–24.
  159. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4(6): 914–9. doi: 10.1111/j.1600-6143.2004.00435.x.
  160. Safinia N, Afzali B, Atalar K, Lombardi G, Lechler RI. T-cell alloimmunity and chronic allograft dysfunction. Kidney Int Suppl. 2010;(119):S2–12. doi: 10.1038/ki.2010.416.
  161. Geissler EK, Hutchinson JA. Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. Curr Opin Organ Transplant. 2013;18(4): 408–15. doi: 10.1097/MOT.0b013e328363319d.
  162. Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can't live without. J Immunol. 2013;191(12): 5785–91. doi: 10.4049/jimmunol.1390055.
  163. Salisbury EM, Game DS, Lechler RI. Transplantation tolerance. Pediatr Nephrol. 2014;29(12): 2263–72. doi: 10.1007/s00467-013-2659-5.
  164. Jones TR, Ha J, Williams MA, Adams AB, Durham MM, Rees PA, Cowan SR, Pearson TC, Larsen CP. The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts. J Immunol. 2002;168(3): 1123–30. doi: 10.4049/jimmunol.168.3.1123.
  165. Sanchez-Fueyo A. Tolerance profiles and immunosuppression. Liver Transpl. 2013;19 Suppl 2:S44–8. doi: 10.1002/lt.23749.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Kildyushevsky A.V., Moysyuk Y.G., Molochkov A.V., Mitina T.A., Faenko A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies